Compare Quest Diagnostics Inc (DGX) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.24. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| DGX | MSTZ | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.02 | $27.92 |
52-Week Low | $166.42 | $3.12 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MSTZ trades at $13.16, up 5.07% today with a bullish technical signal from moving averages. The stock shows neutral oscillators but strong momentum indicators. Key support sits at $13 with resistance at $14. Recent ETF performance news highlights momentum strategies but lacks direct MSTZ coverage.
Outlook hinges on undisclosed fundamentals; current technical strength suggests near-term upside if $14 resistance breaks. Risks include absence of visible financial metrics and reliance on broader market trends. Investors need earnings clarity for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
